Image Source: UnsplashAn IntroductionThis article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies in the munKNEE Psychedelic Compound Based Clinical-Stage Drug Stocks Portfolio with their stock performances last week, in descending order, and their areas of focus, along with their latest news, analyses and commentary where available.Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA. (Source)
- focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- focuses on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
- focuses on the use of LSD and MDMA. Go here for much more extensive information on LSD and here for much more extensive information on MDMA.
SummaryOn average, the above 4 stocks were down 13.0% last week but remain UP 41.1% YTD.More By This Author:Pure Play Quantum Computing Portfolio Down 3% In May
Pure Play Cybersecurity Software Stocks Portfolio Down Almost 4% In May
Pure-Play Cloud Computing SaaS Stocks Portfolio Down 15% In May
